GNI GROUP LTD.
February 13, 2015
February 13, 2015 - GNI Group Ltd. announced today the consolidated and non-consolidated financial results in the fiscal year ending December 31, 2014 increased or decreased compared to the previous fiscal year as indicated below.
1. Consolidated Results
1) Differences of consolidated financial results between the fiscal year ending December 31, 2014 and the fiscal year ending December 31, 2013.
(Unit：JPY Million)
Sales | Operating Profit / Loss | Ordinary Profit / Loss | Net Profit / Loss | Net Profit / Loss per Share | |
Fiscal Year ending December 31, 2014（A） | 474 | △550 | △440 | △327 | △2.91 yen |
Fiscal Year ending December 31, 2013 (B) | 183 | △785 | △781 | △730 | △7.16 yen |
Fluctuation(A）－（B） | 291 | 234 | 340 | 402 | － |
Fluctuation (%) | 158.6% | － | － | － | － |
*Percentages may not total due to rounding
2) Reason for the variances
GNI Group Ltd. recorded consolidated sales of JPY 474 million in the fiscal year ending December 31, 2014, representing a
158.6% year-over-year increase. The increase was primarily the result of the February sales launch of Etuary, the Company's idiopathic pulmonary fibrosis treatment drug, which is manufactured by Beijing Continent Pharmaceutical Co., Ltd., a consolidated subsidiary of the GNI Group, Ltd.
Sales of Etuary were JPY 254 million for the 10 month period from the launch in February to the end of December 2014. Consequently, GNI Group Ltd. achieved the operating profit / loss, ordinary profit / loss, and net profit / loss consolidated financial results for the fiscal year ending December 31, 2014 as described above.
1
2. Non-consolidated Results
1) Differences of non-consolidated financial results between the fiscal year ending December 31, 2014 and the fiscal year ending December 31, 2013.
(Unit：JPY Million)
Sales | Operating Profit / Loss | Ordinary Profit / Loss | Net Profit / Loss | Net Profit / Loss per Share | |
Fiscal Year ending December 31, 2014（A） | 21 | △338 | △253 | △255 | △2.27 yen |
Fiscal Year ending December 31, 2013 (B) | 32 | △194 | △195 | △242 | △2.37 yen |
Fluctuation(A）－（B） | △11 | △143 | △57 | △13 | － |
Fluctuation (%) | △34.4％ | － | － | － | － |
*Percentages may not total due to rounding
2) Reason for the variances
GNI Group Ltd. recorded non-consolidated sales of JPY 21 million in the fiscal year ending December 31, 2014, representing a 34.4% year-over-year decrease.
The decrease was mainly the result of reduced reagent sales by the Company. In addition, SGA expenses of JPY 348 million in 2014 increased by JPY 142 million on a year-over-year basis primarily due to the company's office relocation (please refer to the IR materials dated September 4, 2014). As a result, GNI Group Ltd. achieved the operating profit / loss, ordinary profit / loss, and net profit / loss non-consolidated financial results for the fiscal year ending December 31, 2014 as described
above.
2
|
distributed by
|
